表紙
市場調查報告書

全身性紅斑性狼瘡 (SLE):開發中產品分析

Systemic Lupus Erythematosus - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 264101
出版日期 內容資訊 英文 642 Pages
訂單完成後即時交付
價格
Back to Top
全身性紅斑性狼瘡 (SLE):開發中產品分析 Systemic Lupus Erythematosus - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 642 Pages
簡介

全身性紅斑性狼瘡 (SLE) ,是造成長期慢性發炎性疾病的自體免疫疾病。SLE引發的發炎會影響皮膚和關節、腎臟、腦等器官。發病的各式因素與遺傳、環境、性、荷爾蒙等疾病有關。症侯有很多種,隨時間變化,不過,一般有嚴重的疲勞感、關節的疼痛和腫、頭痛、稱作蝶形紅斑的臉頰和鼻子的皮疹、掉頭髮、貧血等。

本報告提供全身性紅斑性狼瘡 (SLE)的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您夾雜最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃相關資訊等資訊。

簡介

  • 調查範圍

全身性紅斑性狼瘡概要

治療藥的開發

治療藥的評估

開發治療藥的企業

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11754IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Lupus Erythematosus - Pipeline Review, H2 2019, provides an overview of the Systemic Lupus Erythematosus (Immunology) pipeline landscape.

Systemic lupus erythematosus (SLE) is an autoimmune disease that causes a chronic inflammatory condition. The inflammation triggered by SLE affect many organs in the body, including skin, joints, kidneys, brain, and other organs. Several factors have been associated with the disease such as genetics, environment and gender and hormones. Symptoms can vary and can change over time. Common symptoms include severe fatigue, painful or swollen joints, headaches, rash on cheeks and nose called butterfly rash, hair loss and anemia.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Lupus Erythematosus - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Lupus Erythematosus (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 10, 35, 21, 63, 15 and 2 respectively. Similarly, the Universities portfolio in Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 2, 1, 11 and 1 molecule, respectively.

Systemic Lupus Erythematosus (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Systemic Lupus Erythematosus (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Systemic Lupus Erythematosus (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Systemic Lupus Erythematosus (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Lupus Erythematosus (Immunology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Systemic Lupus Erythematosus (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Systemic Lupus Erythematosus - Overview
  • Systemic Lupus Erythematosus - Therapeutics Development
  • Systemic Lupus Erythematosus - Therapeutics Assessment
  • Systemic Lupus Erythematosus - Companies Involved in Therapeutics Development
  • Systemic Lupus Erythematosus - Drug Profiles
  • Systemic Lupus Erythematosus - Dormant Projects
  • Systemic Lupus Erythematosus - Discontinued Products
  • Systemic Lupus Erythematosus - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Systemic Lupus Erythematosus, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..5), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..6), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..7), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..8), H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
  • Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
  • Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Systemic Lupus Erythematosus - Pipeline by AbbVie Inc, H2 2019
  • Systemic Lupus Erythematosus - Pipeline by ACEA Therapeutics Inc, H2 2019
  • Systemic Lupus Erythematosus - Pipeline by Alpine Immune Sciences Inc, H2 2019
  • Systemic Lupus Erythematosus - Pipeline by Aluda Pharmaceuticals Inc, H2 2019
  • Systemic Lupus Erythematosus - Pipeline by Amgen Inc, H2 2019
  • Systemic Lupus Erythematosus - Pipeline by Apellis Pharmaceuticals Inc, H2 2019
  • Systemic Lupus Erythematosus - Pipeline by Apimeds Inc, H2 2019
  • Systemic Lupus Erythematosus - Pipeline by APT Therapeutics Inc, H2 2019
  • Systemic Lupus Erythematosus - Pipeline by Araim Pharmaceuticals Inc, H2 2019

List of Figures

  • Number of Products under Development for Systemic Lupus Erythematosus, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Top 10 Routes of Administration, H2 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Number of Products by Top 10 Molecule Types, H2 2019
  • Number of Products by Stage and Top 10 Molecule Types, H2 2019
Back to Top